MaaT Pharma Announces European Medicines Agency Granted MaaT033 Orphan Drug Designation Aiming to Improve Overall Survival in Patients Undergoing Hematopoietic Stem Cell transplantation 7 September 2023
NeurAxis Highlights Two Independent Studies Showing Benefits of IB-Stim in Adolescents Involving the Gut Microbiome 29 August 2023
MaaT Pharma announces publication of results in eClinicalMedicine Journal highlighting clinical benefit of MaaT013 in aGvHD 28 July 2023
Alphyn Biologics Reports Encouraging Interim Results of Phase 2a Trial for Atopic Dermatitis with Secondary Bacterial Infection 19 July 2023